• LAST PRICE
    16.5900
  • TODAY'S CHANGE (%)
    Trending Up0.1800 (1.0969%)
  • Bid / Lots
    16.5300/ 5
  • Ask / Lots
    16.6900/ 2
  • Open / Previous Close
    16.6000 / 16.4100
  • Day Range
    Low 15.6600
    High 16.8100
  • 52 Week Range
    Low 8.7950
    High 36.4900
  • Volume
    100,056
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 16.41
TimeVolumeBTAI
09:32 ET1849015.9448
09:34 ET783015.75
09:36 ET598815.92
09:38 ET660516.185
09:39 ET204016.3769
09:41 ET1277116.67
09:43 ET600016.8
09:45 ET703216.755
09:48 ET1260816.66
09:50 ET70016.46
09:52 ET50016.55
09:54 ET30016.55
09:56 ET661716.5237
09:57 ET256816.59
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBTAI
BioXcel Therapeutics Inc
459.2M
-4.0x
---
United StatesGBIO
Generation Bio Co
461.3M
-3.5x
---
United StatesALXO
ALX Oncology Holdings Inc
466.6M
-5.1x
---
United StatesAURA
Aura Biosciences Inc
450.9M
0.0x
---
United StatesGRNA
Greenlight Biosciences Holdings PBC
447.2M
-3.7x
---
United StatesPRE
Prenetics Global Ltd
442.8M
29.8x
---
As of 2022-08-08

Company Information

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BXCL501 is also being developed for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia and, under its subsidiary OnkosXcel Therapeutics, BXCL701, is an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naive to checkpoint inhibitors.

Contact Information

Headquarters
555 Long Wharf DrNEW HAVEN, CT, United States 06511-6107
Phone
203-643-8060
Fax
302-636-5454

Executives

Independent Chairman of the Board
Peter Mueller
President, Chief Executive Officer, Director
Vimal Mehta
Chief Financial Officer, Senior Vice President
Richard Steinhart
Senior Vice President, Chief Scientific Officer
Frank Yocca
Senior Vice President, Chief Legal Officer, Corporate Secretary
Javier Rodriguez

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$459.2M
Revenue (TTM)
$0.00
Shares Outstanding
28.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.18
EPS
$-4.12
Book Value
$7.92
P/E Ratio
-4.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.